Reich, K. et al. 2022. Efficacy and safety of ixekizumab versus adalimumab in patients with active psoriatic arthritis and moderate-to-severe psoriasis: 52-week results from the randomised SPIRIT-H2H trial. Dermatology Practical & Conceptual. 12, 2 (May 2022), e2022104. DOI:https://doi.org/10.5826/dpc.1202a104.